Adjuvant Therapy for Pancreas Cancer: Advances and Controversies

Mary Frances Mulcahy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Although the benefit of adjuvant therapy for pancreas cancer is clear, the most effective therapy remains elusive. In the United States, combination therapy with chemotherapy and radiation remains the standard of care, while in other parts of the world the contribution of radiation is questioned. Clinical trials are reported evaluating the benefit of post-resection radiation and chemotherapy with 5-fluoruoracil (5FU), gemcitabine, and combination therapy; chemotherapy alone with either 5FU or gemcitabine; and pre-resection chemotherapy and radiation. Attention to pancreas cancer staging, radiation techniques, and clinical trial design are paramount to interpreting the outcomes from adjuvant therapy. Therapeutic advances will be made with new approaches studied in carefully controlled trials.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalSeminars in Oncology
Volume34
Issue number4
DOIs
StatePublished - Aug 1 2007

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Adjuvant Therapy for Pancreas Cancer: Advances and Controversies'. Together they form a unique fingerprint.

Cite this